During donor evaluation for allogeneic bone marrow transplanmarrow monosomy 7 or del(7)(q22-34) provided evidence tation (BMT) of a 28-month-old child with juvenile chronic myethat familial predisposition to myelodysplasia is not located logeneous leukemia (JCML) with 46,XY,−7,+mar karyotype, the within a consistently deleted segment on the long arm of chropotential donor twin brother was found to be thrombocytomosome 7.
In May 1993, LP presented at 7 months of age with abdominal distension, pallor and lethargy. His physical examination was significant for massive hepatosplenomegaly. A complete Introduction blood count (CBC) revealed a white cell count (WBC) of 70 000/l with a left shift and marked monocytosis, a hemoJuvenile chronic myelogenous leukemia (JCML) is a clonal globin of 5.5 g/dl and a platelet count of 40 000/l. A bone myeloproliferative disorder of early childhood. 1 Confusion in marrow (BM) aspirate revealed 24% erythrocytes, 55% the literature exists over classification of pediatric myelodysmyeloid cells, 11% lymphocytes, 4% lymphoblasts, 2% myeplasia, and the diagnostic criteria which distinguishes JCML loblasts and 4% eosinophils. Hemoglobin F (HbF) was 7%. from infantile monosomy 7 syndrome. Strict diagnostic criteria His clinical and laboratory findings were consistent with of JCML includes progressive thrombocytopenia, elevated JCML. Cis retinoic acid was started and improved his platelet fetal hemoglobin for age, hepatosplenomegaly, monocytosis, count to 80 000/l, but he continued to be red cell transfusion increased serum muramidase (lysozyme) levels and striking dependent. His WBC decreased to 19 000 l and HbF hypersensitivity of peripheral blood hematopoietic progenitors decreased to 0.7%. Massive hepatosplenomegaly remained to GM-CSF. [2] [3] [4] [5] With consideration of these criteria, JCML can and thrombocytopenia worsened and the therapeutic regimen be distinguished from monosomy 7, which is a cytogenetic was changed to ␣-interferon. The patient's clinical status abnormality occurring in a variety of myeloid disorders, improved after splenectomy and he became transfusion indeincluding JCML. A recent review suggests that monosomy 7 pendent. At 28 months of age the patient underwent an allois present at diagnosis in 6-24% of JCML patients, while geneic bone marrow transplant from an older (4-year-old) others may acquire monosomy 7 with progression of the dis-HLA-identical sibling (DP). Conditioning consisted of total ease. 6 Treatment includes aggressive chemotherapy or isotretibody irradiation (1350 cGY as 150 cGY fractions twice a noin (13-cis retinoid acid) but prognosis for these children day × 9 doses), VP-16 (1800 mg/m 2 × 1 dose) and cyclophosremains poor. Allogeneic bone marrow transplantation has phamide (60 mg/kd/d × 2 days); cyclosporin A and short been shown to be curative in a small number of cases. 7 course methotrexate were used as graft-versus-host disease Familial JCML has never been reported, in contrast to the (GVHD) prophylaxis. The transplant course was complicated evidence for familial bone marrow monosomy 7. In a review by cellulitis and pneumonia. Grade I GVHD of the skin of 27 patients with childhood monosomy 7, eight were found occurred on day 40 and resolved with no change in therapy. to be siblings. 8, 9 In all of these cases, however, only one genRelapse of JCML occurred on day 105 following BMT. The eration was affected. Molecular evidence of three additional patient is currently stable on ␣-interferon. affected families with childhood myelodysplasia and bone ZP is the twin of LP. Restriction fragment length polymorphism (RFLP) with five DNA probes determined monozygosity Correspondence: V Najfeld, Tumor Cytogenetics Laboratory, Box with 98% probability (data not shown). At Center, the only cytogenetic analysis of LP was performed by plasma cells, 6% eosinophils, 2% erythroblasts, 3% myeloan outside laboratory when he was 7 months old. As shown blasts, 10% promyelocytes, 8% myelocytes and 6% metamyein Table 1 , on day 28 following BMT, 2/18 cells had locytes. At 32 months of age hepatosplenomegaly developed 46,XY,−7,+mar karytotype and by day 70 the abnormal clone, and repeat BM at this time was consistent with JCML. The comprising of about 6% of dividing cells, had further karyopatient is currently being treated with ␣-interferon and is typic abnormalities. Different clonal karyotypic changes in the doing well.
−7,+mar clone were observed on day 105, when relapse occurred and the rearranged karyotype was present in almost 68% of evaluated metaphases. Table 2 shows the number of Materials and methods Table 2 Summary of interphase FISH analyses using chromosome
Chromosomes from bone marrow specimens were obtained 7 centromeric probe as previously described 10 and ISCN cancer cytogenetic nomenclature was used to describe the karyotype. Systems (Stratford, CT, USA). Table 3 Interphase FISH study with CEP for chromosome 7 of LP Discussion at diagnosis
Childhood monosomy 7 and JCML are clonal disorders affect-
No. of hybridization signals/nuclei (%) Total
ing predominantly boys before the age of 2 and have a poor prognosis. They account for a majority of childhood myeloid
disorders. 6 A rare spontaneous hematological remission was reported in a 14-month-old boy with myelodysplastic syn- gene. 13 In contrast, in the familiar, form of monosomy 7, the data indicate either a gene dosage effect 9 or perhaps genomic imprinting.
14,15 Familial childhood monosomy 7 differs from other forms of childhood monosomy in that females are affected as often as males and the mean age at diagnosis is higher hybridization signals in bone marrow interphase nuclei cells following BMT when probed with CEP for chromosome 7. A than in de novo cases. 6, 9 We are not aware of any reported monozygotic twins with JCML. Thus, sibling donors for copy of the initial report and a diagnostic cell suspension was subsequently obtained from the outside laboratory. The numpatients with de novo monosomy 7 need extensive evaluation, including marrow cytogenetics, prior to being accepted as a ber of cells in 45,XY,−7 and in 46,XY,−7,+mar clones was not available. Interphase and metaphase FISH results are shown marrow donor. 6, 8 Patient ZP was found to be thrombocytopenic when he was in Table 3 and Figure 1 . Two metaphse cells with complex karyotype in a clone showing −7,+mar detected on day 70 evaluated as a possible marrow donor for his twin brother. Bone marrow cytogenetics were not performed at that time. following BMT of LP were destained. One cell on one slide was used for FISH study with CEP for chromosome 7 and the An older HLA-identical sibling was chosen as a donor, with normal cytogenetics. Initial detection of 46,XY,−7,+mar karyoother metaphase on a different slide was subjected to in situ hybridization study with WCP for chromosome 7. Both metatype of LP was on day 28 following BMT. When −7,+mar were detected in 2/34 evaluated cells on day 70 following BMT, phases showed two hybridization signals, on normal chromosome 7 and on mar chromosome, as shown in Figure 2 .
diagnostic report and cell suspension were obtained from the outside laboratory and the subsequent evaluation utilizing During the donor evaluation for allogeneic BMT the monozygotic twin brother, ZP, was found to be thrombocytopenic.
FISH is shown in Table 3 . Two chromosome 7 centromeric hybridization signals were documented in all 54 evaluated Subsequent bone marrow aspirate showed 45,XY,−7,+mar karyotype in all evaluated cells. Table 2 shows the results of metaphases, consistent with retention of chromosome 7 centromeric sequences. Subsequent metaphase FISH analysis of interphase FISH studied using CEP for chromosome 7 on bone marrow cells from ZP. In order to resolve discrepancy mar chromosome, detected in relapsed cells following BMT (Figure 2) , and in diagnostic marrow cells in the twin brother between 100% of proliferating cells with 46,XY,−7,+mar karyotype of ZP and 9.6% of 779 evaluated interphase cells ZP (Figure 3 ), revealed del(7) in both twins. The genotype analysis demonstrated the probability of monozygosity with one hybridization signal, we performed metaphase FISH on destained cytogenetic preparation. All 30 evaluated metabetween the twins on the order of 98%. Of note, LP was diagnosed with JCML at 7 months and ZP at 26 months of age, phases had two hybridization signals either with WCP or with CEP for chromosome 7: one on normal chromosome 7 and respectively. Possible explanations for these observations include transformation in utero of affected cells with cellular the other on the mar chromosome as shown in Figure 3 . The exact breakpoints could not be determined and the karyotype transfer between twins and engraftment or a single 'hit' mutation with eventual appearance of del(7) in both children of both patients was 46,XY,del(7)(p11q?) or del(7)(p?q11).
Figure 1
A representative diagnostic marrow cell of LP after hybridization with CEP for chromosome 7. Note in the left panel two hybridization signals: on normal chromosome 7 and on mar (arrow) chromosome. In the right panel is an enlarged marker chromosome identified as del (7).
Figure 2
A G-banded bone marrow metaphase cell obtained from LP on day 70 post-BMT (left). The arrow points to the marker chromosome. On the right is the same metaphase, which was destained and used for in situ hybridization with CEP for chromosome 7. Note the hybridization signals on normal chromosome 7 and on mar chromosome del(7).
Figure 3
A G-banded metaphase from ZP (left panel) was destained and hybridized with CEP for chromosome 7 (right panel). Hybridization signals are on normal chromosome 7 and on mar chromosome (arrow). Note the similarity of del(7) chromosome in the twins. via cell division and development. Both explanations are conThere have been at least seven patients reported with −7,+mar chromosomal complement in bone marrow cells and sistent with the notion that partial monosomy 7 in these twins was of embryonic origin. Although unlikely, we cannot in each case the mar chromosome was identified with metaphase FISH as a partial monosomy 7. [17] [18] [19] [20] In each of seven exclude the possibility that a partial monosomy 7 had independent origin in both twins either in utero or after birth.
patients reported the mar chromosome was described as a structural abnormality involving pericentromeric material of Recent molecular work, using a series of polymorphic markers on chromosome 7, suggests that loss of alleles located on chromosome 7. Cytogenetic and FISH data of mar chromosome in our two patients fits this description. Metaphase FISH chromosome 7 may not be essential for development of JCML but may contribute to leukemogenesis in some cases. 16 On identified mar chromosome in an additional three patients to be of chromosome 7 origin. 20-22 Therefore, reported patients, the other hand, the loss of chromosome 7 allele represents a hallmark of childhood monosomy 7, which appears to be as well as our two cases, are best described as having a partial deletion of chromosome 7 rather than monosomy 7. Unbaluncommon in JCML. 16 Therefore, Butcher et al 16 proposed a multistep pathogenesis model to distinguish JCML and childanced cryptic translocations of the long arms of chromosome 7 were recently identified through FISH studies in 2/26 hood monosomy 7. According to this model, which may explain only a percentage of cases with monosomy 7 synpatients with myelodysplasia and acute myelogenous leukemia. 23 Therefore, it has been suggested that metaphase FISH drome and JCML, loss of chromosome 7 in JCML is a secondary event in a leukemogenic process. Clinical, cytogenetic with chromosome painting probes be applied to all cases reported as del (7) in order to identify abnormalities in a more and FISH data of our two patients, suggesting an embryonic origin of del (7), may not support Butcher's model, although accurate fashion.
23
The observation that 9% of interphase cells of ZP (Table 2 ) our findings do not necessarily exclude his notion. It is conceivable that heritable mutations or other events contributed and 5.3% of interphase cells of LP (Table 3) showed only one hybridization signal, while 100% of metaphase cells had to development of JCML in utero and that del(7) was a later event in the leukemogenic process that took place during del (7), is consistent with a notion that a structurally abnormal chromosome such as del (7) has a propensity to be lost due to embryonal development. del (7) 
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Concentrations of serum leukemia inhibitory factor (LIF) in patients with hematologic malignancies
Elevated levels of cytokines such as macrophage colony-stimulating factor (M-CSF), interleukin-6 (IL-6) and interleukin-8 (IL-8) were found in the serum of patients with lymphoid and nonlymphoid malignancies. 1,2 These molecules are markers of the exacerbation of cytokine production in patients with hematologic malignancies. Leukemia inhibitory factor (LIF) is a pleiotropic inflammatory cytokine identified by its growth and differentiation activities on hematopoietic cells. [3] [4] [5] Human mesenchymal cells and T cells produce LIF spontaneously or after induction. 6, 7 LIF and IL-6 have some redundant activities such as the stimulation of acute phase protein synthesis. 6 Suggesting a role of LIF during hematopoietic malignancies, marrow stromal cells from patients with various hematological neoplasms showed enhanced constitutive LIF expression as compared to stromal cells from normal marrow. 8, 9 Like other cytokines, circulating LIF concentrations could be valuable as a marker of the exacerbation of cytokine 63 leukemic patients before therapy according to the Helsinki recommendations. Twenty patients had a nonlymphoid malig-(78.9 ± 8.9 pg/ml) while they were not significantly different nancy including 12 acute myeloid leukemia (AML) (mean age in patients with CLL (129.5 ± 63.1 pg/ml, P = 0.07) and AML 60 ± 5, sex ratio man/woman 3) and eight refractory anemia (101.8 ± 18.3 pg/ml, P = 0.14). LIF levels were correlated with with excess of blasts (RAEB) (mean age 74 ± 3, sex ratio 7).
M-CSF levels in patients with HL (r = 0.90, P = 0.0001) and Forty-three patients had a lymphoid malignancy including 25 NHL (r = 0.66, P = 0.0004). LIF and IL-6 levels were not correnon-Hodgkin's lymphoma (NHL) (mean age 62 ± 4 years, sex lated except in patients with RAEB (r = 0.86, P = 0.006). LIF ratio 1.5, 12 Hodgkin's lymphoma (HL) (mean age 43 ± 5 and IL-8 levels were not correlated. years, sex ratio 2), and six chronic lymphocytic leukemia
As for other cytokines detected in higher levels in serum (CLL) (mean age 70 ± 2 years, sex ratio 1). Fifty-five healthy during hematologic malignancies, LIF also represents a marker individuals (mean age 60 ± 3 years, sex ratio 1.2) served as of the exacerbation of cytokine production in patients with controls. Serum LIF levels were measured by an enzyme-HL, NHL and RAEB. Despite redundant activities between LIF linked immunosorbent assay (ELISA) for human LIF as preand IL-6 their circulating levels are not correlated. The viously described. 10 Briefly, specific high titer polyclonal antiabsence of correlation between LIF and IL-8 or IL-6 (except bodies obtained by intra-lymph node immunization of rabbits in RAEB) suggests that the cell sources and/or the mechanisms with recombinant LIF have been used to develop specific, of production leading to LIF, IL-8, and IL-6 synthesis differ accurate and sensitive ELISA. The same batch of purified antibetween the different types of hematologic malignancies. The LIF antibodies has been used for the coating of 96-well plates correlations between LIF and M-CSF levels in HL and NHL (capture antibody) and for the quantitative detection of the are difficult to interpret since no information regarding the bound cytokine molecules (soluble biotinylated antibodies).
sources and relationships of production of M-CSF and LIF in The sensitivity (12 pg/ml), accuracy (intra-assay variation these malignancies is available. Our present results strengthen Ͻ20%) and reproducibility (inter-assay variation Ͻ17%) are the putative role of LIF during hematopoietic malignancies equivalent to those for previously published ELISA. 10 Results previously suggested by data reporting the enhanced constitutare expressed as mean ± s.e.m. Comparison between groups ive LIF expression of marrow stromal cells of patients with was made using Mann-Whitney U-test. A P value Ͻ0.05 was various hematological neoplasms as compared with those considered to be significant. Correlations between serum LIF from controls.
8,9
and serum M-CSF, IL-6, and IL-8 concentrations (previously assessed for these patients 1,2 ) were calculated by linear V Lorgeot Laboratoire d'Hématologie Expérimentale regression analysis. V Praloran Faculté de Médecine As shown in Figure 1 , serum concentrations of LIF were sig-P Turlure 2 rue Dr Marcland nificantly higher in patients with HL (297.1 ± 149.5 pg/ml, Y Denizot 87025 Limoges, France P = 0.005), NHL (196.5 ± 48.6 pg/ml, P = 0.003), and RAEB (191.0 ± 68.7 ± pg/ml, P = 0.02) than in control subjects Acknowledgement V Lorgeot is the recipient of a grant from the Conseil Régional
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